Plain-English translation of NCT06507579 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is evaluating the Hydra transcatheter aortic valve, a new device designed to replace a severely narrowed aortic valve without open-heart surgery. Doctors will implant the valve using a catheter (a thin tube) inserted through your groin artery, and then track how well it works over time.
Severe aortic stenosis (a dangerously narrowed heart valve) limits blood flow and can cause life-threatening symptoms. While valve replacement surgery is available, this trial exists to see if this newer valve option can work just as well with less invasive surgery, potentially offering patients faster recovery and fewer complications.
You likely qualify if…
You likely don't qualify if…
You would receive the Hydra valve replacement procedure at a participating hospital in the UK. After discharge, you would wear a small portable heart monitor for 72 hours to check your heart rhythm, have follow-up clinic visits at 45 days and 1 year to ensure everything is healing well, and provide data on your recovery and valve function. Doctors may also check that your coronary arteries (the blood vessels feeding your heart) are still accessible after the procedure.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United Kingdom